#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hereditary motor and sensory neuropathy Methylmalonic acidaemia Acute graft versus host disease in skin Cholangiocarcinoma Urea cycle disorder Polycythaemia vera Cholangitis sclerosing Porphyria non-acute Brain abscess Ornithine transcarbamoylase deficiency Alveolar rhabdomyosarcoma Sjogren's syndrome Hairy cell leukaemia recurrent Progressive familial intrahepatic cholestasis Non-small cell lung cancer metastatic More trials…

    Learn about Rare Diseases

    KBG syndrome – Diagnostics IgA nephropathy Haemophilia A with anti factor VIII – Diagnostics Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Basic Information Hereditary ataxia Osteosarcoma recurrent – Diagnostics Basal cell naevus syndrome – Diagnostics Cytokine release syndrome – Life with Disease Inclusion body myositis – Treatment Friedreich’s ataxia – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Icatibant Dextrose Bp Piperacillin Immunoglobulin A Propranolol Miglustat AZD3632 Entrectinib Tinzaparin Sodium Somapacitan Db-Oto-3 Ecubectedin Valganciclovir Hydrochloride Casirivimab Interleukin-2 Pyridoxine Hydrochloride Amiloride S-241656 Cenobamate Eftilagimod Alfa More therapies…

    Learn about Your Condition

    Appendicitis Pancreatic carcinoma recurrent Postprandial hypoglycaemia Immune thrombocytopenia Dystonic tremor Carotid artery stenosis Inflammation Type 1 diabetes mellitus Malignant melanoma of eyelid Facial paresis Epileptic encephalopathy Non-Hodgkin's lymphoma Pharyngeal cancer stage II Extra-osseous Ewing's sarcoma Drug use disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Immune thrombocytopenia

  • A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Autoimmune haemolytic anaemia
    • Immune thrombocytopenia
    Investigated Drugs:
    • Tafasitamab
    France Italy The Netherlands Spain

  • A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

    Recruiting

    3 1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Bulgaria Croatia Czechia France Germany Greece +6

  • A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

    Recruiting

    3 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Bulgaria Croatia Czechia France Germany Greece +6

  • Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

    Recruiting

    3 1 1
    Investigated Drugs:
    • Rilzabrutinib
    Austria Czechia France Germany Hungary Italy +3

  • Study of NVG-2089 given by intravenous infusion in patients with immune thrombocytopenia to evaluate safety and effectiveness

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Investigated Drugs:
    • NVG-2089
    • Human Normal Immunoglobulin (Iv)
    Greece Poland Spain

  • Study of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia

    Recruiting

    4 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Investigated Drugs:
    • Efgartigimod Alfa
    France Germany Hungary Italy Lithuania Poland +2
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!